1997
Total skin electron beam therapy followed by adjuvant psoralen/ultraviolet-A light in the management of patients with T1 and T2 cutaneous T-cell lymphoma (mycosis fungoides)
Quirós P, Jones G, Kacinski B, Braverman I, Heald P, Edelson R, Wilson L. Total skin electron beam therapy followed by adjuvant psoralen/ultraviolet-A light in the management of patients with T1 and T2 cutaneous T-cell lymphoma (mycosis fungoides). International Journal Of Radiation Oncology • Biology • Physics 1997, 38: 1027-1035. PMID: 9276369, DOI: 10.1016/s0360-3016(97)00127-2.Peer-Reviewed Original ResearchConceptsTotal skin electron beam therapyDisease-free survivalT2 patientsCrude relapse rateAdjuvant therapyOverall survivalElectron beam therapyRelapse rateEntire cohortMedian disease-free survivalCutaneous T-cell lymphomaBeam therapySalvage of recurrencesAdjuvant systemic therapyEarly-stage patientsManagement of patientsT-cell lymphomaTopical nitrogen mustardDays/weekCombination of therapiesGy/dayTreatments/weekPUVA patientsMedian followSalvage therapy
1996
Additional courses of total skin electron beam therapy in the treatment of patients with recurrent cutaneous T-cell lymphoma
Wilson L, Quiros P, Kolenik S, Heald P, Braverman I, Edelson R, Kacinski B. Additional courses of total skin electron beam therapy in the treatment of patients with recurrent cutaneous T-cell lymphoma. Journal Of The American Academy Of Dermatology 1996, 35: 69-73. PMID: 8682967, DOI: 10.1016/s0190-9622(96)90499-5.Peer-Reviewed Original ResearchConceptsTotal skin electron beam therapyCutaneous T-cell lymphomaRecurrent cutaneous T-cell lymphomaComplete responseT-cell lymphomaElectron beam therapySecond courseMedian disease-free intervalThird courseAdditional coursesBeam therapyDisease-free intervalTreatment of patientsAcceptable risk profileForm of therapyMedian doseMedian survivalMild erythemaPatientsInitial courseTherapyVariety of modalitiesRisk profileEntire groupLocalized radiation
1995
Systemic chemotherapy and extracorporeal photochemotherapy for T3 and T4 cutaneous T-cell lymphoma patients who have achieved a complete response to total skin electron beam therapy
Wilson L, Licata A, Braverman I, Edelson R, Heald P, Feldman A, Kacinski B. Systemic chemotherapy and extracorporeal photochemotherapy for T3 and T4 cutaneous T-cell lymphoma patients who have achieved a complete response to total skin electron beam therapy. International Journal Of Radiation Oncology • Biology • Physics 1995, 32: 987-995. PMID: 7607973, DOI: 10.1016/0360-3016(95)00073-8.Peer-Reviewed Original ResearchConceptsTotal skin electron beam therapyDoxorubicin/cyclophosphamideCutaneous T-cell lymphoma patientsAdjuvant doxorubicin/cyclophosphamideT-cell lymphoma patientsExtracorporeal photochemotherapyComplete responseOverall survivalAdjuvant therapyElectron beam therapyAdjuvant regimenFree survivalCTCL patientsLymphoma patientsBeam therapyAddition of chemotherapyAdvanced stage CTCLClinical complete responseSystemic adjuvant therapyGood partial responseSignificant survival benefitBetter overall survivalRelapse-free survivalSoles of feetNontoxic regimenMalignant melanoma and other second cutaneous malignancies in cutaneous T-cell lymphoma. The influence of additional therapy after total skin electron beam radiation.
Licata AG, Wilson LD, Braverman IM, Feldman AM, Kacinski BM. Malignant melanoma and other second cutaneous malignancies in cutaneous T-cell lymphoma. The influence of additional therapy after total skin electron beam radiation. JAMA Dermatology 1995, 131: 432-5. PMID: 7726585, DOI: 10.1001/archderm.131.4.432.Peer-Reviewed Original ResearchConceptsTotal skin electron beam therapyCutaneous T-cell lymphomaT-cell lymphomaSquamous cell carcinomaBasal cell carcinomaElectron beam therapyAdditional radiation therapyCell carcinomaCutaneous malignanciesOral psoralenAdditional therapyMalignant melanomaRadiation therapyBeam therapyTotal skin electron beam radiationFurther radiation therapyGroup of patientsNonmelanoma skin cancerAnecdotal case reportsPrevious large studiesTopical mechlorethamineHydrochloride therapyCase reportPatientsCarcinomaMalignant Melanoma and Other Second Cutaneous Malignancies in Cutaneous T-Cell Lymphoma: The Influence of Additional Therapy After Total Skin Electron Beam Radiation
Licata A, Wilson L, Braverman I, Feldman A, Kacinski B. Malignant Melanoma and Other Second Cutaneous Malignancies in Cutaneous T-Cell Lymphoma: The Influence of Additional Therapy After Total Skin Electron Beam Radiation. JAMA Dermatology 1995, 131: 432-435. DOI: 10.1001/archderm.1995.01690160060009.Peer-Reviewed Original ResearchTotal skin electron beam therapyCutaneous T-cell lymphomaT-cell lymphomaSquamous cell carcinomaBasal cell carcinomaElectron beam therapyAdditional radiation therapyCell carcinomaCutaneous malignanciesOral psoralenAdditional therapyMalignant melanomaRadiation therapyBeam therapyTotal skin electron beam radiationFurther radiation therapyGroup of patientsNonmelanoma skin cancerAnecdotal case reportsPrevious large studiesTopical mechlorethamineHydrochloride therapyCase reportPatientsCarcinoma
1994
Impact of non-CTCL dermatologic diagnoses and adjuvant therapies on cutaneous T-cell lymphoma patients treated with total skin electron beam radiation therapy
Wilson L, Cooper D, Goodrich A, Friedman N, Feldman A, Braverman I, Kacinski B. Impact of non-CTCL dermatologic diagnoses and adjuvant therapies on cutaneous T-cell lymphoma patients treated with total skin electron beam radiation therapy. International Journal Of Radiation Oncology • Biology • Physics 1994, 28: 829-837. PMID: 8138435, DOI: 10.1016/0360-3016(94)90102-3.Peer-Reviewed Original ResearchConceptsTotal skin electron beam therapySystemic adjuvant therapyRelapse-free survivalDoxorubicin/cyclophosphamide chemotherapyShorter relapse-free survivalElectron beam therapyAdjuvant therapyDermatologic diagnosesBeam therapyCyclophosphamide chemotherapyFollicular mucinosisOverall survivalT2 patientsExtracorporeal photopheresisLymphomatoid papulosisCutaneous relapseTotal skin electron beam radiation therapyCutaneous T-cell lymphoma patientsT-cell lymphoma patientsBetter relapse-free survivalClinical complete responseCohort of patientsElectron beam radiation therapyBeam radiation therapyAdjuvant chemotherapyNovel prognostic factors predictive of prolonged relapse-free and overall survival in advanced stage CTCL (mycosis fungoides) patients treated with total skin electron beam therapy
Kacinski B, Wilson L, Quiros P, Kolenik S, Heald P, Edelson R, Braverman I. Novel prognostic factors predictive of prolonged relapse-free and overall survival in advanced stage CTCL (mycosis fungoides) patients treated with total skin electron beam therapy. International Journal Of Radiation Oncology • Biology • Physics 1994, 30: 268. DOI: 10.1016/0360-3016(94)90823-0.Peer-Reviewed Original ResearchAdditional courses of total skin electron beam therapy [TSEBT] in the retreatment of patients with cutaneous t-cell lymphoma [CTCL]
Wilson L, Quiros P, Kolenik S, Heald P, Braverman I, Edelson R, Kacinski B. Additional courses of total skin electron beam therapy [TSEBT] in the retreatment of patients with cutaneous t-cell lymphoma [CTCL]. International Journal Of Radiation Oncology • Biology • Physics 1994, 30: 269. DOI: 10.1016/0360-3016(94)90825-7.Peer-Reviewed Original Research
1993
Increased incidence of malignant melanoma and other second cutaneous malignancies after total skin electron beam therapy (TSEBT) for CTCL (mycosis fungoldes)
Goodrich A, Wilson L, Braverman I, Kacinski B. Increased incidence of malignant melanoma and other second cutaneous malignancies after total skin electron beam therapy (TSEBT) for CTCL (mycosis fungoldes). International Journal Of Radiation Oncology • Biology • Physics 1993, 27: 187. DOI: 10.1016/0360-3016(93)90728-e.Peer-Reviewed Original ResearchAdjuvant Extracorporeal Photoimmunotherapy or adjuvant adriamyciwcytoxan chemotherapy both prolong survival for cutaneous T-cell lymphoma (CTCL, MYCOSIS FUNGOIDES) patients treated with total skin electron beam therapy (TSEBT).
Kacinaki B, Wilson L, Goodrich A, Edelson R, Heald P, Braverman I. Adjuvant Extracorporeal Photoimmunotherapy or adjuvant adriamyciwcytoxan chemotherapy both prolong survival for cutaneous T-cell lymphoma (CTCL, MYCOSIS FUNGOIDES) patients treated with total skin electron beam therapy (TSEBT). International Journal Of Radiation Oncology • Biology • Physics 1993, 27: 186-187. DOI: 10.1016/0360-3016(93)90727-d.Peer-Reviewed Original Research
1992
The role of novel prognostic factors & adjuvant therapy in CTCL (Mycosis fungoides) patients treated with total skin electron beam therapy
Kacinski B, Murren J, Friedman N, Braverman I, Cooper D. The role of novel prognostic factors & adjuvant therapy in CTCL (Mycosis fungoides) patients treated with total skin electron beam therapy. International Journal Of Radiation Oncology • Biology • Physics 1992, 24: 229. DOI: 10.1016/0360-3016(92)90308-5.Peer-Reviewed Original Research
1991
Repeat courses of either total skin electron beam therapy (TSEBT) or local RT are safe and effective palliation to relapsed CTCL patients whose symptoms are not controlled by other topical or systemic anti-ctcl therapies
Kacinski B, Friedrtan N, Murren J, Cooper D, Braverman I. Repeat courses of either total skin electron beam therapy (TSEBT) or local RT are safe and effective palliation to relapsed CTCL patients whose symptoms are not controlled by other topical or systemic anti-ctcl therapies. International Journal Of Radiation Oncology • Biology • Physics 1991, 21: 212. DOI: 10.1016/0360-3016(91)90608-7.Peer-Reviewed Original Research
1987
Combined total body electron beam irradiation and chemotherapy for mycosis fungoides
Braverman I, Yager N, Chen M, Cadman E, Hait W, Maynard T. Combined total body electron beam irradiation and chemotherapy for mycosis fungoides. Journal Of The American Academy Of Dermatology 1987, 16: 45-60. PMID: 3100583, DOI: 10.1016/s0190-9622(87)70004-8.Peer-Reviewed Original ResearchConceptsComplete clinical remissionElectron beam therapyMycosis fungoidesClinical remissionBeam therapyKaplan-Meier methodElevated blood levelsSignificant differencesGeneralized Wilcoxon testSézary cellsCombination therapyBlood levelsControl subjectsActuarial analysisStage IStage IIIPatientsFungoidesTherapyKaryotypic abnormalitiesMonthly cyclesWilcoxon testRemissionChemotherapyStatistical analysisElectron microscopic and immunolabeling studies of the lesional and normal skin of patients with mycosis fungoides treated by total body electron beam irradiation
Braverman I, Klein S, Grant A. Electron microscopic and immunolabeling studies of the lesional and normal skin of patients with mycosis fungoides treated by total body electron beam irradiation. Journal Of The American Academy Of Dermatology 1987, 16: 61-74. PMID: 3100584, DOI: 10.1016/s0190-9622(87)70005-x.Peer-Reviewed Original ResearchConceptsEpidermal Langerhans cellsElectron beam therapyLangerhans cellsMycosis fungoidesIndeterminate cellsNormal skinDisease courseLesional skinBeam therapySkin lesionsNonspecific skin lesionsPatient's disease courseIa-positive cellsEpidermal cell suspensionsEpidermal thymocyteClinical remissionBiopsy specimensPretreatment levelsIa antigensFungoidesTherapyLesionsSkinPatientsCells